This brand name is authorized in United States.
The drug ASPARLAS contains one active pharmaceutical ingredient (API):
1
|
Calaspargase pegol
UNII
T9FVH03HMZ - CALASPARGASE PEGOL
|
|
Calaspargase pegol is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. |
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| ASPARLAS Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 72694-515 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.